These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 12588361)

  • 1. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation.
    Lee JH; Lee JH; Choi SJ; Kim S; Seol M; Kwon SW; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
    Br J Haematol; 2003 Feb; 120(4):702-10. PubMed ID: 12588361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Lee JS; Kim SH; Kwon SW; Kim WK
    Bone Marrow Transplant; 2000 Jan; 25(2):179-84. PubMed ID: 10673677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of donor-derived isoagglutinins in ABO-Incompatible hematopoietic stem cell transplantation.
    Chung HJ; Lee JH; Kwon SW
    J Clin Lab Anal; 2008; 22(6):383-90. PubMed ID: 19021268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.
    Tomac G; Bojanić I; Mazić S; Vidović I; Raos M; Ćepulić BG; Seiwerth RS; Kelečić J; Labar B
    Blood Transfus; 2018 Jul; 16(4):397-404. PubMed ID: 28488966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
    Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
    Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.
    Stussi G; Halter J; Bucheli E; Valli PV; Seebach L; Gmür J; Gratwohl A; Schanz U; Passweg JR; Seebach JD
    Haematologica; 2009 Feb; 94(2):239-48. PubMed ID: 19144657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation].
    Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Li JP; Zhang T; Zhong J; Chen J
    Hematology; 2007 Apr; 12(2):117-21. PubMed ID: 17454192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Helbig G; Stella-Holowiecka B; Krawczyk-Kulis M; Wojnar J; Markiewicz M; Wojciechowska-Sadus M; Kopera M; Kruzel T; Najda J; Nowak K; Holowiecki J
    Haematologica; 2005 Nov; 90 Suppl():ECR33. PubMed ID: 16266924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
    Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
    Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pure red cell aplasia following ABO-incompatible allogeneic hematopoietic stem cell transplantation].
    Fan H; Jing Y; Li HH; Lu XC; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):364-7. PubMed ID: 18426666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange.
    Curley C; Pillai E; Mudie K; Western R; Hutchins C; Durrant S; Kennedy GA
    Transfusion; 2012 Feb; 52(2):291-7. PubMed ID: 21848968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of pure red cell aplasia using therapeutic plasma exchange after ABO-incompatible hematopoietic stem cell transplant.
    Vivero A; Peedin AR; Gao Y; Karp JK
    J Clin Apher; 2023 Aug; 38(4):495-499. PubMed ID: 36703597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Xu Y; Wu D; Zhong J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Feb; 10(1):61-5. PubMed ID: 12513840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of reemergent anti-B red blood cell antibodies in a patient with recurrent acute myeloid leukemia with ABO-incompatible allogeneic peripheral blood stem cell transplantation.
    Tajima K; Takizawa K; Yasuda T; Tsumanuma R; Okuyama S; Kumagai H; Omoto E; Okumura W
    Transfusion; 2019 Nov; 59(11):3319-3323. PubMed ID: 31503348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation.
    Bolan CD; Leitman SF; Griffith LM; Wesley RA; Procter JL; Stroncek DF; Barrett AJ; Childs RW
    Blood; 2001 Sep; 98(6):1687-94. PubMed ID: 11535498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ABO-incompatible nonmyeloablative allogeneic peripheral blood stem cell transplantation].
    Sun WJ; Guo M; Qiao JH; Yu CL; Wang DH; Sun QY; Zhang S; Li X; Ai HS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):39-42. PubMed ID: 15748433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation.
    Zhu P; Wu Y; Cui D; Shi J; Yu J; Zhao Y; Lai X; Liu L; Xie J; Huang H; Luo Y
    Front Immunol; 2022; 13():829670. PubMed ID: 35222414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors.
    Hirokawa M; Fukuda T; Ohashi K; Hidaka M; Ichinohe T; Iwato K; Kanamori H; Murata M; Sakura T; Imamura M; Adachi S; Suzuki R; Morishima Y; Sakamaki H;
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1026-32. PubMed ID: 23583828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.